At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
OC459 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma
In Brief
A Phase 2 clinical trial evaluating OC459, Placebo, and 1 other intervention for Asthma and 3 related conditions. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The aim of this study is to assess the effectiveness of a CRTH2 receptor antagonist, OC459, in preventing or attenuating the worsening of asthma symptoms during rhinovirus infection. The study is a double blind, randomised trial in which half the subjects will receive OC459 and the other half placebo, before being inoculated with rhinovirus, that would normally induce a worsening of asthma symptoms i.e. an exacerbation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Rhinovirus, Picornaviridae Infections, Common Cold
CountriesUnited Kingdom
CollaboratorsMedical Research Council, Atopix Therapeutics, Ltd.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2016
Primary CompletionFeb 2018
TodayJul 2026
First PostedJan 21, 2016
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.4 years ago
Interventions
OC459drug
Placebodrug
Rhinovirusother
Inoculation with rhinovirus serotype 16